Invesco
VBIV

Invesco’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Invesco’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,688
Closed -$15.3K – 3976
2023
Q1 		$15.3K Sell
1,688
-147
-8% -$2.08K ﹤0.01% 3824
2022
Q4 		$21.5K Sell
1,835
-27,214
-94% -$480K ﹤0.01% 3966
2022
Q3 		$615K Buy
29,049
+6,455
+29% +$174K ﹤0.01% 3143
2022
Q2 		$548K Buy
22,594
+6,602
+41% +$225K ﹤0.01% 3285
2022
Q1 		$797K Buy
15,992
+3,180
+25% +$157K ﹤0.01% 3175
2021
Q4 		$900K Buy
12,812
+2,674
+26% +$225K ﹤0.01% 3123
2021
Q3 		$946K Buy
10,138
+1,067
+12% +$101K ﹤0.01% 3127
2021
Q2 		$913K Sell
9,071
-723
-7% -$70.5K ﹤0.01% 3159
2021
Q1 		$914K Buy
9,794
+1,261
+15% +$128K ﹤0.01% 3085
2020
Q4 		$704K Buy
8,533
+1,219
+17% +$104K ﹤0.01% 3080
2020
Q3 		$628K Buy
7,314
+5,433
+289% +$633K ﹤0.01% 3038
2020
Q2 		$175K Buy
+1,881
New +$104K ﹤0.01% 3508

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco's VBIV Position: Q2 2023 in Review

Invesco sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 1,688 shares — an estimated $15.3K sold.

Invesco first reported a position in VBIV in Q2 2020 and held it in 12 quarters. The position peaked at $946K in Q3 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Invesco reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Invesco sold 1,688 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $15.3K.
  • Invesco first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2020 and held it in 12 quarters.
  • Invesco's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $946K in Q3 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.